Investigational treatment for vascular cognitive impairment

Bibliography

• O’BRIEN JT, ERKINJUNTTI T, REISBERG B et al.: Vascular cognitive impairment. Lancet Neurol. (2003) 2(2):89-98.
   PubMed Web of Science ®Google Scholar
• EBLY EM, HOGAN DB, PARHAD IM: Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. Arch. Neurol. (1995) 52(6):612-619.
   Google Scholar
• GRAHAM JE, ROCKWOOD K, BEATTIE BL et al.: Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet (1997) 349(9068):1793-1796.
   PubMed Web of Science ®Google Scholar
• ROCKWOOD K, WENTZEL C, HACHINSKI V et al.: Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology (2000) 54(2):447-451.
   PubMed Web of Science ®Google Scholar
• NEUROPATHOLOGY GROUP.MEDICAL RESEARCH COUNCIL COGNITIVE FUNCTION AND AGING STUDY: Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet (2001) 357(9251):169-175.
   PubMed Web of Science ®Google Scholar
• HEYMAN A, FILLENBAUM GG, WELSH-BOHMER KA et al.: Cerebral infarcts in patients with autopsy-proven Alzheimer’s disease: CERAD, part XVIII. Consortium to establish a registry for Alzheimer’s disease [erratum appears in Neurology (1998) 51(6):1809]. Neurology (1998) 51(1):159-162.
   PubMed Web of Science ®Google Scholar
• SNOWDON DA, GREINER LH, MORTIMER JA et al.: Brain infarction and the clinical expression of Alzheimer’s disease. The Nun Study. JAMA (1997) 277(10):813-817.
   PubMed Web of Science ®Google Scholar
• O’BRIEN MD: How does cerebrovascular disease cause dementia? Dementia (1994) 5(3-4):133-136.
   PubMedGoogle Scholar
• GEARING M, MIRRA SS, HEDREEN JC et al.: The Consortium to establish a Registry for Alzheimer’s disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer’s disease. Neurology (1995) 45(3 Part 1):461-466.
   PubMed Web of Science ®Google Scholar
• HACHINSKI V: Preventable senility: a call for action against the vascular dementias. Lancet (1992) 340(8820):645-648.
   PubMed Web of Science ®Google Scholar
• HACHINSKI VC, ILIFF LD, ZILHKA E et al.: Cerebral blood flow in dementia. Arch. Neurol. (1975) 32(9):632-637.
   Google Scholar
• SIMARD D, OLESEN J, PAULSON OB, LASSEN NA, SKINHOJ E: Regional cerebral blood flow and its regulation in dementia. Brain (1971) 94(2):273-288.
   PubMed Web of Science ®Google Scholar
• ROMAN GC: Vascular dementia: Proceedings of the NINDS-AIREN International Workshop on Vascular Dementia. NIH, Bethesda, MD 19 – 21 April 1991. New Issues in Neurosciences (1992) 4:79-183.
   Google Scholar
• ROMAN GC, TATEMICHI TK, ERKINJUNTTI T et al.: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 43(2):250-260.
   PubMed Web of Science ®Google Scholar
• THE WORLD HEALTH ORGANIZATION: The ICD-10 classification of mental and behavioural disorders. Clinical Descriptions and Diagnostic Guidelines (1992).
   Google Scholar
• STEWART R, LIOLITSA D: Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet. Med. (1999) 16(2):93-112.
   Google Scholar
• MEYER JS, MURAMATSU K, MORTEL KF, OBARA K, SHIRAI T: Prospective CT confirms differences between vascular and Alzheimer’s dementia. Stroke (1995) 26(5):735-742.
   PubMed Web of Science ®Google Scholar
• DESMOND DW, TATEMICHI TK, PAIK M, STERN Y: Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. Arch. Neurol. (1993) 50(2):162-166.
   Google Scholar
• ROCKWOOD K, EBLY E, HACHINSKI V, HOGAN D: Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch. Neurol. (1997) 54(1):33-39.
   Google Scholar
• UEDA K, KAWANO H, HASUO Y, FUJISHIMA M: Prevalence and etiology of dementia in a Japanese community. Stroke (1992) 23(6):798-803.
   PubMed Web of Science ®Google Scholar
• ANTIPLATELET TRIALISTS’ COLLABORATION: Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients [erratum in Br. J. Med. (1994) 308(6943):1540]. Br. Med. J. (1994) 308(6921):81-106.
   PubMed Web of Science ®Google Scholar
• BATH PMW, BATH-HEXTALL FJ: Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke [update of Cochrane Database Syst. Rev. (2000) 2:CD000162; PMID: 10796310]. Cochrane Database Syst. Rev. (2004) 3:CD000162.
   PubMedGoogle Scholar
• FRAMPTON M, HARVEY RJ, KIRCHNER V: Propentofylline for dementia. Cochrane Database Syst. Rev. (2003) 2:CD002853.
   PubMedGoogle Scholar
• FLICKER L: Pentoxifylline in the treatment of vascular dementia. In: Evidence-Based Dementia Practice. Qizilbash N SL, Chiu H, Tariot P, Brodaty H, Kaye J, Erjinjuntti T (Eds), Blackwell Science, Oxford, UK (2002) xxii:893.
   Google Scholar
• LOPEZ A, BIRKS J: Nimodipine for primary degenerative, mixed and vascular dementia [update in Cochrane Database Syst. Rev. (2002) 3:CD000147; PMID: 12137606] [update of Cochrane Database Syst. Rev. (2000) 2:CD000147; PMID: 10796495]. Cochrane Database Syst. Rev. (2001) 1:CD000147.
   PubMedGoogle Scholar
• BRIEL M, STUDER M, GLASS TR, BUCHER HC: Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med. (2004) 117(8):596-606.
   PubMed Web of Science ®Google Scholar
• CROW TJ, GROVE-WHITE IG: An analysis of the learning deficit following hyoscine administration to man. Br. J. Pharmacol. (1973) 49(2):322-327.
   Web of Science ®Google Scholar
• SCHWARZ RD, CALLAHAN MJ, COUGHENOUR LL et al.: Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. J. Pharmacol. Exp. Ther. (1999) 291(2):812-822.
   Google Scholar
• ZHANG W, EDVINSSON L, LEE TJ: Mechanism of nicotine-induced relaxation in the porcine basilar artery. J. Pharmacol. Exp. Ther. (1998) 284(2):790-797.
   Google Scholar
• BOWEN DM, SMITH CB, WHITE P, DAVISON AN: Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain (1976) 99(3):459-496.
   PubMed Web of Science ®Google Scholar
• DAVIES P, MALONEY AJ: Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet (1976) 2(8000):1403.
   PubMed Web of Science ®Google Scholar
• MANN DM, YATES PO, MARCYNIUK B: Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer’s disease and their relationship to ageing and to the accumulation of lipofuscin pigment. Mech. Ageing Dev. (1984) 25(1-2):189-204.
   PubMed Web of Science ®Google Scholar
• PERRY EK, GIBSON PH, BLESSED G, PERRY RH, TOMLINSON BE: Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci. (1977) 34(2):247-265.
   Google Scholar
• GOTTFRIES CG, BLENNOW K, KARLSSON I, WALLIN A: The neurochemistry of vascular dementia. Dementia (1994) 5(3-4):163-167.
   PubMedGoogle Scholar
• TOHGI H, ABE T, KIMURA M, SAHEKI M, TAKAHASHI S: Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J. Neural. Transm. (1996) 103(10):1211-1220.
   Google Scholar
• WILKINSON D, DOODY R, HELME R et al.: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology (2003) 61(4):479-486.
   PubMed Web of Science ®Google Scholar
• BLACK S, ROMAN GC, GELDMACHER DS et al.: Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke (2003) 34(10):2323-2330.
   PubMed Web of Science ®Google Scholar
• FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. (1975) 12(3):189-198.
   Google Scholar
• ROSEN WG, MOHS RC, DAVIS KL: A new rating scale for Alzheimer’s disease. Am. J. Psychiatry (1984) 141(11):1356-1364.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER LS, OLIN JT, DOODY RS et al.: Validity and reliability of the Alzheimer’s disease Cooperative Study – Clinical Global Impression of Change. The Alzheimer’s disease Cooperative Study. Alzheimer Dis. Assoc. Disord. (1997) 11(Suppl. 2):S22-S32.
   Google Scholar
• BERG L: Clinical Dementia Rating (CDR). Psychopharmacol. Bull. (1988) 24(4):637-639.
   Web of Science ®Google Scholar
• LAWTON MP, BRODY EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist (1969) 9(3):179-186.
   PubMed Web of Science ®Google Scholar
• ERKINJUNTTI T, KURZ A, GAUTHIER S et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet (2002) 359(9314):1283-1290.
   PubMed Web of Science ®Google Scholar
• GELINAS I, GAUTHIER L, MCINTYRE M, GAUTHIER S: Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. Am. J. Occup. Ther. (1999) 53(5):471-481.
   Web of Science ®Google Scholar
• CUMMINGS JL, MEGA M, GRAY K et al.: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology (1994) 44(12):2308-2314.
   PubMed Web of Science ®Google Scholar
• AUCHUS AP BRASHEAR H, SALLOWAY S et al.: Results of a trial of galantamine in subjects with vascular dementia confirmed by central MRI reading. Proceedings of the 56th Annual Meeting of the American Academy of Neurology. San Francisco, USA (April 24 – May 1 2004).
   Google Scholar
• SCHELTENS P BH, ZHU Y, VAN STRAATEN ECW, BARKHOF F, GASSMANN-MAYER C: Effect of galantamine on cognition in subgroups of patients with vascular dementia. Proceedings of the 12th International Psychogeriatric Association. Stockholm, Sweden (20 – 24 September 2005).
   Google Scholar
• GALASKO D, BENNETT D, SANO M et al.: An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s disease Cooperative Study. Alzheimer Dis. Assoc. Disord. (1997) 11(Suppl. 2):S33-S39.
   PubMed Web of Science ®Google Scholar
• SUCHER NJ, AWOBULUYI M, CHOI YB, LIPTON SA: NMDA receptors: from genes to channels. Trends Pharmacol. Sci. (1996) 17(10):348-355.
   Web of Science ®Google Scholar
• ORGOGOZO J-M, RIGAUD A-S, STOFFLER A, MOBIUS H-J, FORETTE F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke (2002) 33(7):1834-1839.
   PubMed Web of Science ®Google Scholar
• WILCOCK G, MOBIUS HJ, STOFFLER A, GROUP MMM: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int. Clin. Psychopharmacol. (2002) 17(6):297-305.
   Google Scholar
• LOEB C, GANDOLFO C: Diagnostic evaluation of degenerative and vascular dementia. Stroke (1983) 14(3):399-401.
   PubMed Web of Science ®Google Scholar
• ROSEN WG, TERRY RD, FULD PA, KATZMAN R, PECK A: Pathological verification of ischemic score in differentiation of dementias. Ann. Neurol. (1980) 7(5):486-488.
   Google Scholar
• AMERICAN PSYCHIATRICASSOCIATION: Diagnostic and Statistical Manual of Mental Disorder (3rd Edition). American Psychiatric Association, Arlington, USA (1987) xxix:567.
   Google Scholar
• BRUNNER C, SPIEGEL R: [A validation study of the nurses’ observation scale for geriatric patients in psychogeriatrics]. Zeitschrift fur Klinische Psychologie (1990) 19(3):211-229.
   Google Scholar
• GUY W: US Department of Health, Education and Welfare. ECDEU Assessment Manual for Psychopharmacology (1976).
   Google Scholar
• GOTTFRIES CG, BRANE G, GULLBERG B, STEEN G: A new rating scale for dementia syndromes. Arch. Gerontol. Geriatr. (1982) 1(4):311-330.
   Google Scholar